2016
DOI: 10.1007/s00216-016-9879-z
|View full text |Cite
|
Sign up to set email alerts
|

An integrated lab-on-a-chip-based electrochemical biosensor for rapid and sensitive detection of cancer biomarkers

Abstract: Recent advances in the area of biosensor technology and microfluidic applications have enabled the miniaturisation of the sensing platforms. Here we describe a new integrated and fully automated lab-on-a-chip-based biosensor device prototype (MiSens) that has potential to be used for point-of-care cancer biomarker testing. The key features of the device include a new biochip, a device integrated microfluidic system and real-time amperometric measurements during the flow of enzyme substrate. For ease of use, a … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
27
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 50 publications
(27 citation statements)
references
References 30 publications
0
27
0
Order By: Relevance
“…Finally, we want to highlight a work in which the authors described an integrated and fully automated lab‐on‐a‐chip‐based biosensor device prototype (MiSens) for point‐of‐care cancer biomarker testing . This lab‐on‐a‐chip system uses a silicon oxide microchip with gold working electrodes.…”
Section: Ed Based On Nanomaterials In Microfluidicsmentioning
confidence: 99%
“…Finally, we want to highlight a work in which the authors described an integrated and fully automated lab‐on‐a‐chip‐based biosensor device prototype (MiSens) for point‐of‐care cancer biomarker testing . This lab‐on‐a‐chip system uses a silicon oxide microchip with gold working electrodes.…”
Section: Ed Based On Nanomaterials In Microfluidicsmentioning
confidence: 99%
“…The field of integrated microfluidic biomarker analysis has been growing rapidly. Just in recent years, new microfluidic platforms for biomarker analysis have emerged with capabilities for colorimetric or electrochemical assays , ELISA , and other biosensors . However, a common disadvantage of most of these studies is that they were only capable of analyzing a single analyte per device.…”
Section: Introductionmentioning
confidence: 99%
“…Currently, most diagnostic tests done in centralized laboratories and hospitals. By using expensive equipment that requires highly trained staff, the use of biosensors has facilitated diagnostic technologies, so that work with it done by patients themselves or by medical staff [8][9][10][11].…”
Section: Cancer and Biosensormentioning
confidence: 99%